Mode
Text Size
Log in / Sign up

Adrenal insufficiency is first manifestation in 73.6% of APS patients with adrenal involvement

Adrenal insufficiency is first manifestation in 73.6% of APS patients with adrenal involvement
Photo by julien Tromeur / Unsplash
Key Takeaway
Consider APS in patients with unexplained adrenal insufficiency, especially with bilateral adrenal hemorrhage.

This systematic review and pooled individual-patient analysis examined 155 published patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE)-spectrum disease who had adrenal involvement, with 143 patients entering the main analysis set. The study aimed to characterize the adrenal imaging phenotype, adrenal insufficiency chronology, immunologic profile, thrombotic burden, treatment/follow-up variables, CAPS presentation context, and outcomes.

Key findings include that 67.1% of patients had primary APS, 86.3% had bilateral adrenal involvement, and 73.6% presented with adrenal insufficiency as the first manifestation of their disease. Hemorrhage-dominant adrenal injury occurred in 66.9% of cases. Hypotension was reported in 48.0% (60/125), strict adrenal crisis in 51.6% (64/124), hyponatremia in 33.1% (47/142), and hyperkalemia in 42.5% (57/134). Catastrophic APS (CAPS) was reported in 59.8% of patients.

The authors note that careful terminology helps separate adrenal vascular injury, adrenal insufficiency, and strict adrenal crisis while preserving the need for urgent endocrine rescue and systemic thrombotic evaluation. Limitations of the study were not explicitly reported in the input. The findings underscore the importance of considering APS in patients presenting with unexplained adrenal insufficiency, especially when bilateral adrenal hemorrhage is present.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Adrenal involvement is a rare but potentially severe immunothrombotic manifestation of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE)-spectrum disease. Because the term adrenal crisis should be reserved for patients with acute adrenal insufficiency accompanied by hypotension or shock, this review distinguishes adrenal vascular injury, adrenal insufficiency, and strict adrenal crisis. We performed a systematic review and individual-patient pooled analysis of published cases of APS/SLE-spectrum adrenal involvement through March 31, 2026. The initial database search was performed from inception to February 10, 2026 and was updated through March 31, 2026. The study selection followed PRISMA 2020 principles, and the protocol was registered in PROSPERO (CRD420261298329). Published patients were harmonized for diagnosis stratum, precipitating trigger, adrenal imaging phenotype, adrenal insufficiency chronology, immunologic profile, thrombotic burden, treatment/follow-up variables, CAPS presentation context, and outcomes. A total of 103 studies comprising 155 published patients were included; 143 entered the main analysis set. The median age was 43.8 years, 49.0% were female, and primary APS accounted for 67.1% of the main cohort. Hemorrhage-dominant adrenal injury was the leading imaging phenotype (66.9%), bilateral adrenal involvement was highly prevalent (86.3% of informative cases), and adrenal insufficiency was the first manifestation in 73.6% of informative cases. Among codable main-analysis cases, hypotension was documented in 60/125 (48.0%), strict adrenal crisis in 64/124 (51.6%), hyponatremia in 47/142 (33.1%), and hyperkalemia in 57/134 (42.5%). CAPS was treated as a presentation/severity context rather than as a downstream consequence and was reported in 59.8% of evaluable patients. Adrenal involvement in APS and lupus-spectrum disease is a heterogeneous but clinically recognizable high-risk phenotype characterized by bilateral adrenal injury, hemorrhagic predominance, frequent sentinel presentation as adrenal insufficiency, and substantial CAPS burden. Careful terminology helps separate adrenal vascular injury, adrenal insufficiency, and strict adrenal crisis while preserving the need for urgent endocrine rescue and systemic thrombotic evaluation. https://www.crd.york.ac.uk/prospero/, identifier CRD420261298329.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.